ERGIC1 and prostate cancer: The mRNA expression of AIM1, ERGIC1, TMED3, and TPX2 was studied in six prostate cancer (VCaP, PC-3, MDA-PCa-2b, LNCaP, DU145 and 22Rv1) and three non-malignant prostate epithelial cell lines (RWPE-1, PrEc, EP156T) (Figure 3A).